Evidence map›Paper›PMID 40734704›Full record

ArticleMolecular therapy. Methods & clinical development2025

A novel pseudotype derived of the canine distemper virus for adapter-mediated lentiviral transduction

Nora Winter, Carolin Kolbe, Shima Ferdos, Larissa Steiner, Nils Bartelsen, Dominik Lock, Fabian Engert, Boris Engels, Mario Assenmacher, Michael Schindler and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nora WinterMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Carolin KolbeMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Shima FerdosMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Larissa SteinerMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Nils BartelsenMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Dominik LockMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Fabian EngertMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Boris EngelsMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Mario AssenmacherMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Michael SchindlerInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, 72076 Tübingen, Germany.
Ulrich M LauerDepartment of Internal Medicine VIII, Medical Oncology and Pneumology, University Hospital Tübingen, 72076 Tübingen, Germany.
Thomas SchaserMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.
Nicole CordesMiltenyi Biotec B.V. & Co KG, 51429 Bergisch Gladbach, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted cell entry with lentiviral vectors (LVs) is one approach to enable efficient and specific gene delivery in the context of immunotherapies, such as chimeric antigen receptor (CAR)-T cell therapy. We have recently shown the generation of CAR-T products with varying CD4:CD8 ratios with our selective, universal Adapter-LV system. However, low viral vector titers limit the clinical and

Indexed as

Adapter-LVcanine distemper virusCAR T cellsgene therapyimmunotherapylentiviral vectorspseudotype

Identifiers

PMID40734704
PMCPMC12305328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.